evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

10 questions · 11 findings · 2 reviews · Schizophrenia

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 6 · 54.5%Low 0 · 0%Moderate 5 · 45.5%High 0 · 0%

STANDARD LOWER DOSE (> 3 to 7.5 mg/day) vs OTHER DOSES

Leaving the study early (2‐10 weeks) vs. standard higher dose (> 7.5‐15 mg/day) · people with the acute phase of schizophrenia

It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes leaving the study early (2‐10 weeks) vs. standard higher dose (>… compared with OTHER DOSES (very low certainty).

1 finding from 1 review

STANDARD LOWER DOSE (> 3 to 7.5 mg/day) vs OTHER DOSES

Global state: No clinically significant response (as defined by the original studies) · people with the acute phase of schizophrenia

It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes global state: 1. No clinically significant response in global state… compared with OTHER DOSES (very low certainty).

1 finding from 1 review

STANDARD LOWER DOSE (> 3 to 7.5 mg/day) vs OTHER DOSES

Global state: 1. No clinically significant response in global state (2‐10 weeks) vs. high dose (> 15‐35 mg/day) · people with the acute phase of schizophrenia

It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes global state: 1. No clinically significant response in global state… compared with OTHER DOSES (very low certainty).

1 finding from 1 review

STANDARD LOWER DOSE (> 3 to 7.5 mg/day) vs OTHER DOSES

Adverse effects: 1. Clinically significant extrapyramidal side effects (2‐10 weeks) vs. standard higher dose (> 7.5‐15 mg/day) · people with the acute phase of schizophrenia

It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes adverse effects: 1. Clinically significant extrapyramidal side… compared with OTHER DOSES (very low certainty).

1 finding from 1 review

STANDARD LOWER DOSE (> 3 to 7.5 mg/day) vs OTHER DOSES

Adverse effects: 1. Clinically significant extrapyramidal side effects (2‐10 weeks) vs. high dose (> 15‐35 mg/day) · people with the acute phase of schizophrenia

It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes adverse effects: 1. Clinically significant extrapyramidal side… compared with OTHER DOSES (very low certainty).

1 finding from 1 review

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) vs ANY DOSE ‐ short term

Leaving the study early: Any reasons ‐ when compared with standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in leaving the study early: Any reasons ‐ when compared with… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) vs ANY DOSE ‐ short term

Leaving the study early: any reason ‐ when compared with high dose ( greater than or equal to 10 mg) · patients with schizophrenia

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in leaving the study early: Any reasons ‐ When compared with high dose… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) vs ANY DOSE ‐ short term

Global state: No clinically important improvement ‐ global evaluation ‐ when compared with standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in global state: No clinically important improvement ‐ global… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) vs ANY DOSE ‐ short term

Mental state: No clinically important improvement · patients with schizophrenia

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in mental state: No clinically important improvement ‐ PANSS ‐ when… compared with ANY DOSE ‐ short term (moderate certainty).

2 findings from 1 review